MUC16 and ovarian cancer: We replicated this finding using CRISPR/Cas9 knockout of MUC16/CA125 in two different ovarian cancer cell lines and showed the same EMT transition associated with increased invasiveness, migration, and loss of sensitivity to BITE-mediated cytotoxicity.